Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Itraconazole for Secondary Prevention of Metaplasia and Primary Prevention of Cancer in Patients With High-risk Barrett's Esophagus in Combination With Ablation

NCT06732388 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06732388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Itraconazole for Secondary Prevention of Metaplasia and Primary Prevention of Cancer in Patients With High-risk Barrett's Esophagus in Combination With Ablation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
June 23, 2026
Completion date
December 1, 2030
Enrollment
76 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

barrett esophagus, clinical stage i esophageal adenocarcinoma ajcc v8, clinical stage iia esophageal adenocarcinoma ajcc v8, esophageal adenocarcinoma